The automation platform for radiation oncology.

Mountain View, CA
Joined August 2012
Radiotherapy can play an important role across the full spectrum of #ProstateCancer, from early-stage to more advanced disease. This #ProstateCancerAwarenessMonth, I hope more men talk with their doctors about their individual risk & potential options. Every treatment decision is personal. Grateful for all of the scientific research that provides us the evidence & clinical guidelines to tailor care for each cancer patient, every day. @PCFnews @ASTRO_org @ASCO @Movember @WorldRTDay @AmericanCancer @AACR
Every September we mark Prostate Cancer Awareness Month. This year it’s more personal for me. More than 330,000 American men this year will hear the words we did last spring when I was diagnosed with prostate cancer. By the time we found it, it had already spread to my bones. When prostate cancer is caught early, the five-year survival is close to 100%. So have the conversation with your doctor. Don’t put it off. If you're at average risk, that conversation should start around 50, and the guidelines now say screening every 2 to 4 years. If you're a Black man, start it at 45 or earlier. You are nearly 70% more likely to get this disease and 2 to 4 times more likely to die from it. Which is an outrage in the richest country in the world. If your father or your brother had prostate cancer, start the conversation at 45, and even earlier if more than one of them did. I am deeply grateful to the doctors, nurses and other medical professionals who helped to control my cancer and who continue to take such good care of me. Their skill, dedication, and compassion mean so much. The radiation treatment from last fall worked as intended, and I continue to do the things I care about, like finishing my memoir. Thank you to everyone who has reached out and continues to keep me and my family in your prayers. We appreciate every single one of you. It’s my hope and prayer that by sharing our experience and being part of this important conversation, we can help save lives. Talk to your doctors. Ask the hard questions. Do it for yourself, and do it for the people who love you. And no matter what, keep the faith. God bless you.
4
11
42
3,287
It was an absolute pleasure to chat with @mcuban about a broad range of topics, from the challenges affecting #healthcare to drug pricing innovation, AI & defining value in #oncology. Always appreciate your fresh perspective, Mark - thank you for sharing it with our Radiation Oncology community!
New ASTRO President’s Corner – featuring Mark Cuban In Part 1, ASTRO President @NehaVapiwala, MD, FASTRO, sits down with Mark Cuban of “Shark Tank,” founder of the Mark Cuban Cost Plus Drug Company. Together, they tackle the current state of the healthcare sector, projecting future physician shortages and discussing the heavy burden insurance authorizations place on daily clinical practice. Watch/listen to parts 1 & 2 on YouTube: bit.ly/459Mjpe Spotify: bit.ly/4gdXQdp ASTRO's website: bit.ly/455r7Rp @costplusdrugs @mcuban
1
7
39
2,152
MedLever retweeted
Begin #ASTRO26 in style at ASTRO’s all-new Welcome Kickoff! Join us Saturday evening, Sept. 26, at the iconic Citizens House of Blues Boston for a celebration for both newcomers and seasoned members of the ASTRO community. Tickets include all-access entry, a live band, plentiful hors d’oeuvres, and two drink tickets. Add a ticket to your ASTRO 2026 registration today! Register by August 13 to save: ow.ly/3n7J50ZavtV
1
5
13
1,325
MedLever retweeted
Today, ASTRO brought together leaders from industry and across the field for our inaugural AI Roundtable to discuss the evolving role of artificial intelligence in radiation oncology and patient care. Thank you to Fuse Oncology, MedLever, Novartis, Siemens Healthineers and Merck for sponsoring this important conversation. Learn more about ASTRO's AI initiatives Rad Onc Report on AI: ow.ly/3oH150Z4RQW Spring 2026 ASTROnews article: ow.ly/wsQX50Z4RQU #RadOnc #AI @fuseoncology @MedLever @Novartis @SiemensHealth @Merck @NehaVapiwala
1
5
1
22
3,451
Replying to @ASTRO_org
@ASTRO_org is grateful to all who have shared their situation & continues to seek member feedback @ our dedicated Payer Support and Resolution Center resource page. 🙏🏽 astro.org/advocacy/payer-res…
Breaking News: ASTRO releases Medicare payment impacts survey results, meets with CMS ASTRO’s national survey shows Medicare payment changes are causing financial harm to clinics & threatening access to radiation therapy. ASTRO met with CMS today to share findings, highlight the urgent challenges for practices, especially in community settings, & discuss solutions. Read the ASTRO Press Release: ow.ly/ApEH50YBX8E #RadOnc #Medicare #Healthcare @OncologyCOA @TheUSONetwork @CMSGov @DrOzCMS @SecKennedy
3
7
1,267
Cancer’s impact transcends borders. Mission-driven @ASTRO_org members like @TamerRefaatMD are leading ASTRO’s charge to address #radiotherapy care access & quality on a global scale. His words are inspiring, but it’s his actions - alongside those of many other committed colleagues - that will move the needle. Come listen & learn how to get more involved!
NEW President's Corner Member Spotlight - Tamer Refaat, MD, PhD, MSCI In the latest ASTRO President's Member Spotlight, ASTRO President Neha Vapiwala, MD, FASTRO, speaks with Tamer Refaat, MD, PhD, MSCI, vice-chair of the ASTRO International Committee, about the new ASTRO International Ambassadors program. @NehaVapiwala @TamerRefaatMD Watch the video: ow.ly/ruFQ50XT6jZ
4
10
691
**ANNOUNCEMENT** Our growth continues with strategic expansions and our recruiting for FOUR (yes 4) new physicians to join our remarkable team! Includes the Vice Chair of Research, Director of Brachytherapy, and two additional clinical-academic faculty positions Read more... @NicholasZaorsky @angela_jia_ @lauren_henke @Soum_Roy_RadOnc @HaleyPerlow @APrice_BeamOn @NRGonc @ACRORadOnc @ARRO_org @ASCO @IJROBP @RadOncUH @a_dalpra @AmarUKishan @HimanshuNagarMD @PCFnews @urotoday
2
18
2
81
14,565
MedLever retweeted
ASTRO is deeply disturbed by the inaccurate, inappropriate, and irresponsible NBC News piece on IORT. We feel this story harms care for breast cancer patients & have strongly rebutted it through our Breast Cancer Resource Panel & a letter from ASTRO CEO, Vivek S Kavadi, MD to NBC News. Read each here: Breast Resource Panel Statement ow.ly/aicz50X9ty1 Letter to NBC News from Dr. Vivek S. Kavadi ow.ly/Hvy550X9txZ
2
51
5
130
23,187
MedLever retweeted
Missing #ASTRO25 already? Watch ASTRO's 2025 Annual Meeting onDemand. Access more than 200 hours of scientific and educational content from leading experts & claim 190+ AMA PRA Category 1™ CME credits. All available on the 2025 Annual Meeting Portal. Learn more and purchase now: ow.ly/mRJ650X5L5p
4
1
6
2,222
Terrific thread by @seanmmcbride While it is important to keep an open mind when faced with bizarre results, the raw survival numbers are almost incomprehensible. In the ITT population: - In the IMRT arm, there were 29 recurrences (Table 1) and 23 deaths due to cancer (Table S1). - In the IMPT arm, there were 25 recurrences and 11 deaths due to cancer. - Thus, 79% of IMRT recurrences led to cancer-specific mortality, versus only 44% of IMPT recurrences. In the PP population: - In the IMRT arm, there were 23 recurrences and 27 deaths (Fig 3b), of which 10 were without progression (Table 1). We don’t know further causes of death. - In the IMPT arm, there were 23 recurrences and only 16 deaths, of which 9 were without progression. - Thus, 74% (17/23) IMRT recurrent patients died, and only 30% (7/23) IMPT recurrent patients died. These survival after salvage numbers aren’t just statistically significant, they are miraculous. To have 70% of R/M HNSCC alive after IMPT has to reflect something beyond biology. I’m looking forward to the final publication and analysis, but there is a “know it when you see it" phenomenon with confounding, and that appears to hold here.
1/n Agree. David and team ran an outstanding trial. And I think there's less discordance btw TORPEDO and the MDA RCT than the discourse suggests. Both trials are essentially demonstrating some QOL/tox benefits for protons in the end-of-treatment/immediate post tx periods. Rate of 12 mon G tube dependence are minimal in both arms in both trials. And the PFS/OS end-points at 3 years are consistent (no benefit to proton). brief🧵#ASTRO25 #hncsm
2
8
16
3,309
🚀 Instant Documentation, Zero Hassle In just 2-5 minutes, you can complete clinical radiotherapy documentation and launch all care paths from a single interaction. ✅ Fast: Generate high-quality, customized documents instantly ✅ Smart: Automation ensures accuracy and consistency ✅ Seamless: Signed documents sync directly with your EMR ⚡ Work smarter, streamline documentation, and stay focused on patient care. 📍 lnkd.in/gxtf2vWw
108
🤝 True Partnership, Real Impact with MedLever At MedLever, we understand the importance of true partnership. When we collaborate with clinics, it's about creating workflows that work best for them. From the initial implementation to ongoing revisions, we're committed to optimizing the platform to fit each clinic's unique needs. Our focus is on: ✨ Customization – Tailoring workflows to your specific processes ✨ Personalization – Adapting the platform to meet your goals ✨ Collaboration – Partnering with your team for continuous improvement With MedLever, clinics gain a lifetime commitment to support and assistance—because patient outcomes come first.
152
As we look back and reflect on a year of growth, innovation, and collaboration. 2024's achievements have brought us closer to our mission of advancing patient care and operational excellence. Thank you to our clients and partners for making this success possible—here’s to an even brighter 2025! 🌱
1
1
99
9/ Revolutionizing workflows with our end to end custom built learning health system for radonc with @MedLever. Led by @RaedZuhour , our team built a learning radiation oncology EMR—fully automating orders, documentation, nursing tasks, billing, and physics workflows. Gets better and better every iteration.
2
2
13
1,946
MedLever retweeted
We are one week away from the #ASTRO23 Annual Meeting & there is still time to register! Register today: ow.ly/Ov2Y50POm10
9
16
3,055
Are you attending #ASTRO23? Come check us out at Booth 3523. @medlever is the air-traffic control for your clinic and the digital assistant for your #radonc workflow. See our automation engine simplify documentation and our electronic task-tracking whiteboards keep the whole department in sync. See you in San Diego!
10
33
2
294
36,373
Help your #radonc team spend less time on paperwork and more time on patient care. Register: us02web.zoom.us/webinar/regi… #radonc #HealthcareInnovation #rpa #Automation
1
2
4
1,523
MedLever retweeted
**HIRING @ UH Seidman Cancer Center's @RadOncUH** Calling Medical Physicists- We are recruiting! Excited to announce we have grown by >40% in past 2 yrs, and have 4 new LINACs soon to go live and innovative new software @MedLever @RaySearch @KashaniRojano @DrSpratticus
1
11
2
23
8,665
A new year brings new breakthroughs in #oncology. In 2023, the oncology space will focus on: 🟣 Genetic Testing 🟣 Targeted Immunotherapies 🟣 Finding and Treating Cancer at the Same Time 🟣 And More! What are you most excited to see in the oncology space in the new year?
113